Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Histrelin acetate is a gonadotropin-releasing hormone agonist. The current U.S. histrelin implant Supprelin LA treats central precocious puberty in children. A separate 50 mg histrelin implant called Vantas was used for palliative treatment of advanced prostate cancer and is listed in the 2026 FDA Orange Book discontinued drug section.
read more about histrelin ...Histrelin initially stimulates pituitary GnRH receptors and temporarily raises luteinizing hormone and follicle-stimulating hormone secretion. Continued exposure then suppresses gonadotropin release and lowers gonadal sex steroid production. In central precocious puberty, this suppresses premature pubertal hormone activity.
Current Supprelin LA labeling covers children with central precocious puberty. Safety and efficacy are not established in children younger than 2 years. Historical Vantas labeling covered adults with advanced prostate cancer, but that product is listed by FDA as discontinued.
Supprelin LA uses one 50 mg subcutaneous implant in the inner upper arm every 12 months. The implant releases about 65 mcg of histrelin acetate each day and is removed after 12 months. Another implant can be inserted at removal when continued hormonal suppression is needed.
Current Supprelin LA warnings include an initial hormone surge, implant breakage or extrusion, psychiatric symptoms, convulsions, severe skin reactions, and pseudotumor cerebri. Gonadotropins and estradiol or testosterone are checked after implantation, and growth and bone age are followed during treatment.
Supprelin LA treats central precocious puberty in children.
One 50 mg implant is placed under the skin of the inner upper arm every 12 months.
No. FDA lists the Vantas histrelin implant in the discontinued drug product section of the 2026 Orange Book.
Yes. GnRH agonist activity can temporarily raise sex hormone concentrations early in treatment before suppression develops.
DailyMed - SUPPRELIN LA (histrelin acetate) implant. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8fb000e-3cc9-4803-b71d-2cc597661977. Date Accessed October 1, 2026.
Histrelin. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548064/. Date Accessed October 1, 2026.
Histrelin. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Histrelin. Date Accessed October 1, 2026.
Histrelin Implant. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a601146.html. Date Accessed October 1, 2026.
SUPPRELIN LA - Orphan Drug Designations and Approvals. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=212605. Date Accessed October 1, 2026.